Aligos Therapeutics SEC filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing therapies for liver and viral diseases. Its Form 8-K reports furnish results of operations, business progress updates, clinical and regulatory events for pevifoscorvir sodium, and material agreements such as the exclusive license for development and commercialization in Greater China.
Proxy materials cover annual meeting procedures, stockholder voting matters, board governance, and compensation-related disclosures. Other current reports document executive officer appointments, compensatory arrangements, exhibit filings, and the company’s common stock listed on the Nasdaq Capital Market under ALGS.
Aligos Therapeutics reports a Schedule 13G filing disclosing beneficial ownership by Lawrence M. Blatt. The filing states the Reporting Person beneficially owns 286,213 shares of Common Stock, representing 5.1% of the class, based on 5,388,223 shares outstanding as of May 1, 2026.
The ownership mix includes directly held shares, trusts, an IRA, 12,206 shares underlying exercisable warrants, and 185,591 shares underlying stock options exercisable or exercisable within 60 days of March 31, 2026.
Aligos Therapeutics, Inc. ownership update: Woodline Partners LP reports beneficial ownership of 239,362 shares of Voting Common Stock, representing 4.4% of the class based on 5,387,807 shares outstanding as of March 2, 2026. The count includes 62,000 shares issuable upon exercise of warrants.
The filing clarifies sole voting and dispositive power over the reported shares and is presented by Woodline as investment adviser to Woodline Master Fund LP. The statement is an ownership disclosure amendment and does not itself effect any transaction.
Aligos Therapeutics reported Q1 2026 results with revenue from customers of $2.8 million, driven mainly by a milestone under its Amoytop collaboration, and a net loss of $23.0 million.
The company spent $23.4 million on research and development and $6.4 million on general and administrative expenses, reflecting ramp-up of its Phase 2 B‑SUPREME trial for HBV candidate pevifoscorvir sodium. Cash, cash equivalents and short‑term investments totaled $54.9 million as of March 31, 2026.
Management states that existing cash, including an expected $25 million upfront payment from a new Greater China license with Amoytop for pevifoscorvir sodium, will fund operations into the fourth quarter of 2026. Because this runway extends for less than one year from the filing date, recurring losses and negative operating cash flows have raised substantial doubt about Aligos’ ability to continue as a going concern without additional capital.
The new Amoytop license grants exclusive HBV rights in Greater China and could provide up to $420 million in milestones plus tiered high single‑digit royalties, while Aligos retains rights in the US, Europe and other major markets. Key clinical programs include pevifoscorvir sodium for chronic HBV, ALG‑055009 for MASH and obesity, and ALG‑097558 for coronavirus infections.
Aligos Therapeutics, Inc. reported first quarter 2026 results with revenue of $2.83M and a net loss of $23.0M, or $2.21 per share. Cash, cash equivalents and investments totaled $54.9M as of March 31, 2026 and are expected to fund operations into the fourth quarter of 2026.
During the quarter, pevifoscorvir sodium for chronic HBV infection received Fast Track Designation from the FDA and delivered a positive first interim analysis in the Phase 2 B-SUPREME study, with study continuation and good tolerability. Aligos also signed an exclusive Greater China license with Amoytop that includes a $25M upfront payment and up to $420M in milestones plus tiered royalties.
Aligos Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on June 25, 2026. Holders of 5,388,223 shares of voting common stock as of April 27, 2026 can participate. Proposals include re-electing two Class III directors, ratifying Ernst & Young LLP as auditor for 2026, and amending the 2020 Employee Stock Purchase Plan to remove its evergreen feature and lift the share reserve to 694,714 shares, an increase of 500,000. Stockholders will also cast advisory votes on 2025 executive compensation and on how often future Say-on-Pay votes should occur, with the Board recommending an annual frequency.
Aligos Therapeutics, Inc. entered a regional license agreement with Xiamen Amoytop Biotech for its investigational Hepatitis B therapy pevifoscorvir sodium. Amoytop receives exclusive rights to develop, manufacture and commercialize the drug in mainland China, Taiwan, Hong Kong and Macau.
Aligos will receive an upfront cash payment of $25 million, and may earn up to $420 million in additional development, regulatory and commercial milestones, plus tiered high single-digit royalties on net sales. Amoytop will fund and lead development, regulatory work, manufacturing and commercialization in the territory, while both parties share certain data and intellectual property under perpetual, largely royalty-free cross-licenses.
Aligos Therapeutics filed an update highlighting interim Phase 2 data and a key regulatory milestone for its hepatitis B drug candidate pevifoscorvir sodium. An independent safety board reviewed early results from the B-SUPREME study and recommended continuing the trial while increasing the sample size in the HBeAg- cohort to strengthen statistical power, noting that futility criteria were not met. The company remains blinded to individual patient data. Enrollment has reached 74 participants in the HBeAg- cohort and 103 in the HBeAg+ cohort, with about 200 patients planned overall, and topline data targeted for 2027. The FDA has granted Fast Track Designation to pevifoscorvir sodium, based on Phase 1 data showing it was well tolerated with promising reductions in multiple viral markers, potentially supporting a faster and more interactive regulatory review path for this chronic hepatitis B program.
Aligos Therapeutics reported that officer Julian A. Symons received a grant of stock options as part of his compensation. The award covers 23,310 stock options to buy Aligos common stock at an exercise price of $7.03 per share.
These options were granted on March 9, 2026 and vest over time. According to the terms, 1/48th of the options vest each month, starting from March 9, 2026, so that the entire grant becomes fully vested and exercisable on the fourth anniversary of that date, if he continues in service through each vesting date.
Aligos Therapeutics, Inc. principal accounting officer Nikhil Aneja received a grant of stock options covering 9,450 shares of common stock at an exercise price of $7.0300 per share. These options were awarded as compensation and do not represent an open-market purchase or sale.
According to the vesting terms, 1/48th of the total options vest in equal monthly installments starting on March 9, 2026, so all 9,450 options are scheduled to be fully vested and exercisable by the fourth anniversary of that vesting commencement date, contingent on continued service.